Table 1.

Clinical characteristics of exome-sequenced T-LGL leukemia patients and patients with STAT5b mutation

No.	LGL leukemia type	Mutations	Sex	Age at diagnosis, y	WBC count at diagnosis, 109/L	Lymph count at diagnosis, 109/L	Lymphocyte count, 109/L*	CD8+ Vβ †	Concomitant disorders	Therapy‡
1	CD3+CD8+CD56+ T cell	STAT5b Y665F	F	71	11.8	7.0	8.5	Vb22, 91%	Collagenosis	No
2	CD3+CD8+CD56+ T cell	STAT5b Y665F	F	49	16.1	12.9	13.7	Vb17, 94%	None	No
3	CD3+CD8+CD56+ T cell	STAT5b N642H	M	74	90.0	85.5	85.5	Vb21, 87%§	Pancytopenia, neutropenia, splenomegaly	Yes
4	CD3negCD56+ NK cell	STAT5b N642H	M	75	164.7	131.8	131.8	Vb7, 27%§Vb3, 16%§	Hemolytic anemia, neutropenia, splenomegaly, MGUS	Yes

F, female; M, male; MGUS, monoclonal gammapathy of unknown significance; WBC, white blood cell.

^*Lymphocyte count at the time point when the sample was taken.

^†Proportion of Vβ clone of CD8⁺ cells.

^‡Pharmacological treatment at any time point.

^§Proportion from total T-cell fraction.